Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | GABRE | P78334 | 2/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047990 | 0.89 | ECE1 (0.38) | ECE1SIGMAR1BBOX1GABRPGABRD | |
| SCHEMBL25553531 | 0.83 | ECE1 (0.39) | ARG1ARG2ECE1BBOX1GABRP | |
| SCHEMBL2179403 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL5595901 | 0.80 | ECE1 (0.42) | ARG1ARG2ECE1BBOX1GABRP | |
| SCHEMBL18814474 | 0.79 | GGT1 (0.38) | ECE1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL19069934 | 0.77 | ALDH1A1 (0.39) | ARG1ARG2ECE1GABRPGABRD | |
| SCHEMBL25553023 | 0.76 | LMNA (0.39) | ARG1ARG2 | |
| SCHEMBL29954080 | 0.72 | ECE1 (0.40) | ECE1SIGMAR1BBOX1GABRPGABRD | |
| SCHEMBL10527389 | 0.72 | ECE1 (0.42) | ECE1SIGMAR1BBOX1GABRPGABRD | |
| SCHEMBL23513804 | 0.72 | KDM4E (0.41) | ECE1SIGMAR1BBOX1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ARG1 12/4885ARG2 32/4885ECE1 2679/4885 |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ARG1 12/4885ARG2 32/4885ECE1 2679/4885 |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ARG1 9/4885ARG2 23/4885ECE1 2007/4885 |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ARG1 12/4885ARG2 32/4885ECE1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.